These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 20019017)
1. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Costero O; Picazo ML; Zamora P; Romero S; Martinez-Ara J; Selgas R Nephrol Dial Transplant; 2010 Mar; 25(3):1001-3. PubMed ID: 20019017 [TBL] [Abstract][Full Text] [Related]
2. Sunitinib-induced thrombotic microangiopathy. Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203 [TBL] [Abstract][Full Text] [Related]
3. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Park CY Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356 [TBL] [Abstract][Full Text] [Related]
4. Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma. Quintyne KI; Neenan T; Casserly L; Gupta R BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24872478 [TBL] [Abstract][Full Text] [Related]
9. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report. Furuto Y; Hashimoto H; Namikawa A; Outi H; Takahashi H; Horiuti H; Honda K; Shibuya Y BMC Nephrol; 2018 Oct; 19(1):273. PubMed ID: 30340546 [TBL] [Abstract][Full Text] [Related]
10. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319 [TBL] [Abstract][Full Text] [Related]
11. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma. Liu YC; Chang PM; Liu CY; Yang CY; Chen MH; Pan CC; Chen MH Jpn J Clin Oncol; 2011 Nov; 41(11):1277-81. PubMed ID: 21965162 [TBL] [Abstract][Full Text] [Related]
12. Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma. Mir-Bonafé JM; Cañueto J; Bravo J; de Unamuno P Int J Dermatol; 2013 Nov; 52(11):1445-7. PubMed ID: 23432117 [No Abstract] [Full Text] [Related]
13. [New drugs; sunitinib and sorafenib]. van Bronswijk H; Dubois EA; Osanto S; Cohen AF Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434 [TBL] [Abstract][Full Text] [Related]
15. Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report. Hanna RM; Selamet U; Hasnain H; El-Masry M; Saab S; Wallace WD; Yanny B; Wilson J Transplant Proc; 2018 Dec; 50(10):4033-4037. PubMed ID: 30577309 [TBL] [Abstract][Full Text] [Related]
16. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Wong MK; Jarkowski A Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623 [TBL] [Abstract][Full Text] [Related]
17. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer]. van der Veldt AA; van den Eertwegh AJ; Boven E Ned Tijdschr Geneeskd; 2007 May; 151(20):1142-7. PubMed ID: 17557672 [TBL] [Abstract][Full Text] [Related]